(Reuters) - Champix, the first new prescription product for smoking
cessation, targets the specific receptor to which nicotine
binds, thereby reducing the severity of the smoker's urge to
smoke.
The medicine is sold as Chantix in the United States. It was
approved as safe and effective by European and U.S. regulators
last year.
Read more at Reuters.com Government Filings News
cessation, targets the specific receptor to which nicotine
binds, thereby reducing the severity of the smoker's urge to
smoke.
The medicine is sold as Chantix in the United States. It was
approved as safe and effective by European and U.S. regulators
last year.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment